Recombinant Human Thrombopoietin Accelerates the Recovery of Platelet in Patients With Lower-Risk Myelodysplastic Syndrome: A Proof-of-Concept Study

AIM: The effect of recombinant human thrombopoietin (rhTPO) is largely unknown in lower-risk myelodysplastic syndrome (LR-MDS). This study aimed at investigating the safety and efficacy of rhTPO in patients with LR-MDS. METHODS: LR-MDS patients receiving stanozolol (2 mg, t.i.d.) and supportive care...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yuan, Tang, Zengwei, Ji, Jiang, Yang, Chen, Chen, Miao, Han, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581467/
https://www.ncbi.nlm.nih.gov/pubmed/34778037
http://dx.doi.org/10.3389/fonc.2021.721764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581467/
https://www.ncbi.nlm.nih.gov/pubmed/34778037
http://dx.doi.org/10.3389/fonc.2021.721764

Ejemplares similares